Merck announced that Frank Clyburn, executive vice president and president, Human Health, will leave Merck on Feb. 1, 2022, to assume a leadership opportunity with another company. Leadership of Human Health following Frank’s departure will be announced in the coming weeks.
“I am extremely appreciative of Frank’s significant contributions to our company during his fourteen years with Merck. Frank has been a key catalyst for value creation, an incredible business strategist, a dedicated people leader and a fierce advocate for patients everywhere,” said Robert M. Davis, chief executive officer and president, Merck. “Frank’s strategic and operational excellence helped establish Merck as a global leader in oncology. Our human health business has delivered strong and sustainable growth under Frank’s leadership, and we are well-positioned to continue this momentum with the strong human health team we have in place.”
Clyburn joined Merck in 2008 and held several leadership positions with increasing responsibility throughout his Merck career. In March 2021, Clyburn was named president of Human Health. Previously, Clyburn served as chief commercial officer for Human Health, and was the president of Merck’s global oncology business. During his time at Merck, he also managed multiple global pharmaceutical franchises, including diabetes, cardiovascular and women’s health, and led numerous marketing and sales teams.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!